This is great news for MVP and has the potential to unlock huge growth for them.

I am confident the "green whistle" will pass clinical trials in the US with flying colours, given it's already got a long history of use in both Australia and Europe.

With the issues the US is facing with opioids, it presents a massive benefit for the clinical treamtent of acute pain without the drawbacks of being high addictive.

It should be a no-brainer for the US but given the power and influence weilded by the big pharma companies in the US, I can see them throwing roadblocks in the way.